Skip to main
NDRA

NDRA Stock Forecast & Price Target

NDRA Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ENDRA Life Sciences Inc. is poised to benefit significantly from anticipated FDA approval within the next year, which could drive stock performance substantially according to a Net Present Value (NPV) analysis indicating considerable upside potential. The TAEUS technology is expected to provide a more accurate and cost-effective means of diagnosing and monitoring Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), addressing an urgent need in the healthcare market where current diagnostic tools are inadequate. Moreover, the application of TAEUS beyond liver conditions into areas such as energy-based surgical procedures further underscores the platform's versatility and potential for broad clinical impact.

Bears say

ENDRA Life Sciences Inc reported a net loss of $1.6 million, translating to an earnings per share (EPS) of $(2.10), which fell short of internal estimates of $(1.95). The company is also experiencing significant balance sheet and liquidity risks, compounded by the challenges of demonstrating the safety and efficacy of its product in clinical trials, as well as obtaining the necessary regulatory approvals for commercialization. Additional factors contributing to a negative outlook include potential difficulties in securing appropriate reimbursement, intense competition, and changes in investor sentiment within the biotech and medtech sectors.

NDRA has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ENDRA Life Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ENDRA Life Sciences (NDRA) Forecast

Analysts have given NDRA a Strong Buy based on their latest research and market trends.

According to 1 analysts, NDRA has a Strong Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ENDRA Life Sciences (NDRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.